Abstract:Heparin-induced thrombocytopenia (HIT) with thrombosis (HITT) is a clinicopathological syndrome caused by IgG antibodies binding to heparin-platelet factor 4 (PF4), creating an immune complex which activates platelets and produces a hypercoagulable state. This results in thrombocytopenia and thrombosis, arising usually 5 to 10 days (range 4–15 days) following heparin exposure.[1] Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare prothrombotic syndrome associated with adenoviral vector-based ChAdOx1 CoV-19 vaccine (AstraZeneca, University of Oxford) or Ad26.COV2.S vaccine (Janssen; Johnson & Johnson).[2] VITT is characterized by thrombocytopenia and thrombosis, often at unusual sites such as cerebral venous sinus thrombosis (CVST), with the development of IgG antibodies which also bind to PF4 but without dependence on heparin or previous heparin exposure.[2] The full extent of the similarity and difference between these two related syndromes has not been fully described. We therefore, compared the incidences, characteristics, and clinical outcomes of HIT in patients with coronavirus disease 2019 (COVID-19), exposed to heparin from a multicenter observational study (coagulopathy associated with COVID-19 [CA-COVID-19]; https://www.clinicaltrials.gov/ct2/show/NCT04405232) with those published for VITT following ChAdOx1 CoV-19 vaccination in the United Kingdom,[3] and also HIT in patients admitted to hospitals without COVID-19.[4] Of 5,971 patients with COVID-19 admitted to 30 National Health Service (NHS) Trusts across the United Kingdom from the first wave of the COVID-19 pandemic (between April 1, 2020, and July 31, 2020), 26 patients developed HIT at a median 13 (6–27) days following exposure to heparin, making an incidence of 0.43%. Of these 26 patients, 25 (96%) developed HITT (i.e., HIT with associated thrombosis). The median age of the patients who developed HITT was 47 (range 35–73) years. The reported incidence of HIT in the United States is approximately 1 in 1,500 hospital admissions (0.067%).[4] Patients undergoing cardiopulmonary bypass had the highest rates of HIT followed by patients on hemodialysis, while patients who undertook hip and knee arthroplasty had the lowest rates of HIT.[4] In general, it appears that lower frequencies are seen with low-molecular weight heparin (LMWH) versus unfractionated heparin (UFH), prophylactic versus therapeutic doses, medical versus surgical patients, and minor versus major trauma.[5] [6] Although there are no nationwide studies assessing the incidence of HIT in patients admitted to hospitals in the United Kingdom, we anticipate that it is similar to that of the published U.S. study.[4] Although several factors have been reported to affect the incidence of HIT including, as stated in the prior cited studies,[4] [5] [6] such as type of heparin (LMWH vs. UFH), prophylactic versus treatment dose heparin, duration of heparin exposure, type of patients studied (medical vs. surgical) and type of surgery, findings are not necessarily consistent between studies. Furthermore, the number of patients included in published studies vary and most include only small numbers of patients. Based on the data reported by May 12, 2021, the estimated incidence of VITT was approximately 7 to 10 cases per million persons receiving ChAdOx1 CoV-19 vaccine (309 VITT cases were reported from the 32.9 million doses given in the United Kingdom) and approximately 3.2 cases per million for the Ad26.COV2.S (or 28 cases out of 8.7 million doses administered in the United States).[7] The incidence of VITT varied according to age and was at least 1:100,000 and 1:50,000 among patients ≥50 or <50 years, respectively, in the United Kingdom.[8] In the United Kingdom-wide study of 294 patients who were evaluated for possible VITT, 170 were classified as definite and 50 as probable cases of VITT.[3] Of these patients, median time to diagnosis of VITT following vaccination in the United Kingdom cohort was 14 (range 5–48) days, with a median age of 48 years (range 18–79).[3] Fifty-four percent (119/217) of VITT patients were female compared with only five female patients in our HIT cohort (19.2%, 5/26; p = 0.0007). Pulmonary embolism (PE; 11/26, 42.3%) was the most frequent thrombotic complication in patients with HIT ([Fig. 1]), whereas CVST was the most common thrombotic complication in patients with VITT, accounting for 50% (110/220) of events, followed by PE alone (35%).[3] All patients diagnosed with HIT were treated with argatroban, compared with 68% patients with VITT, the remainder receiving a variety of other nonheparin-based anticoagulants.[3] There was no difference in the overall mortality among patients: 23.0% (6/26) in patients with HIT versus 22.3% (49/220) in VITT, p = 0.99. This is similar to the mortality reported in patients with H -Abstract Truncated-

Heparin-induced Thrombocytopenia with Thrombosis in COVID-19 versus Vaccine-induced Immune Thrombocytopenia and Thrombosis in the United Kingdom

Cerebral Venous Thrombosis in Patients With Heparin-Induced Thrombocytopenia a Systematic Review.

Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder

Fc γ RIIa - dependent platelet activation identified in COVID-19 vaccine-induced immune thrombotic thrombocytopenia-, heparin-induced thrombocytopenia, streptokinase- and anisoylated plasminogen-streptokinase activator complex-induced platelet activation

Mechanisms of Thrombosis in Heparin-Induced Thrombocytopenia and Vaccine-Induced Immune Thrombotic Thrombocytopenia

Antibodies against Platelet Glycoproteins in Clinically Suspected VITT Patients

Heparin-Induced Thrombocytopenia in COVID-19: A Systematic Review

Whole Blood Procoagulant Platelet Flow Cytometry Protocol for Heparin-Induced Thrombocytopenia (HIT) and Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Testing

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

Heparin-Induced Thrombotic Thrombocytopenia (HITT) and Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Similar but Different

COVID-19 Vaccine-Associated Immune Thrombosis and Thrombocytopenia (VITT): Diagnostic Discrepancies and Global Implications

Anti-PF4 VITT antibodies are oligoclonal and variably inhibited by heparin

Thrombotic Complications after COVID-19 Vaccination: Diagnosis and Treatment Options

Understanding vaccine-induced thrombotic thrombocytopenia (VITT)

Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria

ChAdOx1 nCoV-19 Vaccine and Thrombosis with Thrombocytopenia Syndrome among Adults: A Systematic Review

Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination

A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines

Damage-associated cellular markers in the clinical and pathogenic profile of vaccine-induced immune thrombotic thrombocytopenia

Vaccine induced thrombotic thrombocytopenia: The shady chapter of a success story

Heparin-induced thrombocytopenia is associated with a high risk of mortality in critical COVID-19 patients receiving heparin-involved treatment